Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“New Data: CAR-T Outcomes in Extranodal DLBCL
Extranodal (EN) DLBCL has long been linked to worse survival, but how do these patients fare after CAR-T therapy? A new multi-center study sheds light:
218 patients with EN DLBCL treated with CAR-T in the relapsed/refractory setting
Most common EN sites: Skin/soft tissue (25%), Bone (22%), Lung (17%)
Overall Response Rate (ORR): 62% | Complete Response Rate (CRR): 40%
Median PFS: 4 months | Median OS: 25.7 months
High-risk factors for worse OS: ≥3 prior therapy lines, bulky disease, liver/pancreas involvement
CRS and ICANS were consistent with known CAR-T safety profiles. Future studies are needed to optimize CAR-T outcomes in high-risk EN DLBCL subgroups, especially those with hepatobiliary involvement.”
Title: Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study
Authors: Frederique St-Pierre, Subodh Bhatta, Peter G. Doukas, Madeline Jenkin, Kaitlin Annunzio, Alexandra E. Rojek, Alyssa Gibson, Yun Kyoung Tiger, Brittany McCall, Khaled Alhamad, Alec Hansen, Juan P. Alderuccio, Olutobi Adewale, Keem Patel, Asaad Trabolsi, Izidore S. Lossos, Lindsey Fitzgerald, Thomas A. Ollila, Matthew J. Matasar, Justin Kline, Reem Karmali, Narendranath Epperla
Read the Full Article.
More posts featuring Yan Leyfman on OncoDaily.